GlaxoSmithKline (GSK) has developed pazopanib, a VEGFR, PDGFR, and cKit inhibitor, for the treatment of RCC and soft tissue sarcoma, and it may also be effective against NSCLC and ovarian cancer [53]. Here, KDR is linked to non-small cell lung carcinoma.